Baird Medical Investment vs Orchestra BioMed
BDMD and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDMD and OBIO compare
Orchestra BioMed grew revenue faster over the last twelve months (1007% versus −39.2% for Baird Medical Investment).
Baird Medical Investment keeps more of each dollar of sales as profit, with a net margin of −121% compared with −183% at Orchestra BioMed.
Orchestra BioMed scores higher on the StockData Score (9 against 2 for Baird Medical Investment), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDMD | OBIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $436M |
| Share price | $0.090 | $7.25 |
| Change, 1 year | −93.0% | 64.0% |
| Change, 5 years | – | −26.5% |
| Beta (5Y) | −0.05 | 0.84 |
| Employees | 146 | 86 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 14.0× |
| FCF yield | – | −14.7% |
| Growth | ||
| Revenue growth (TTM) | −39.2% | 1007% (better) |
| Net income growth (TTM) | −319% | – |
| EPS growth (TTM) | −272% | – |
| Profitability | ||
| Gross margin | 83.8% | 99.6% (better) |
| Operating margin | −114% (better) | −195% |
| Net margin | −121% (better) | −183% |
| FCF margin | −6.2% (better) | −206% |
| Return on equity | −77.5% | – |
| Return on invested capital | −48.2% | – |
| Financial health | ||
| Debt / equity | 0.22 | – |
| Interest coverage | −72.3× | – |
| Current ratio | 1.29 | 7.25 (better) |
| Altman Z-score | – | −3.18 |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 46.1% |
| Held by insiders | 62.0% | 56.6% |
| Insider net buying, 12 months | – | $6.1M |
| Short interest, % of float | – | 10.5% |
Go deeper
- BDMD stock overview
- BDMD income statement
- BDMD valuation and score
- OBIO stock overview
- OBIO income statement
- OBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.